Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation by Hartz, Susanne et al.
RESEARCH ARTICLE Open Access
Evaluating the cost effectiveness of donepezil in
the treatment of Alzheimer’s disease in Germany
using discrete event simulation
Susanne Hartz
1, Denis Getsios
2*, Sunning Tao
3, Steve Blume
4 and Grant Maclaine
5
Abstract
Background: Previous cost-effectiveness studies of cholinesterase inhibitors have modeled Alzheimer’s disease (AD)
progression and treatment effects through single or global severity measures, or progression to “Full Time Care”.
This analysis evaluates the cost-effectiveness of donepezil versus memantine or no treatment in Germany by
considering correlated changes in cognition, behavior and function.
Methods: Rates of change were modeled using trial and registry-based patient level data. A discrete event
simulation projected outcomes for three identical patient groups: donepezil 10 mg, memantine 20 mg and no
therapy. Patient mix, mortality and costs were developed using Germany-specific sources.
Results: Treatment of patients with mild to moderately severe AD with donepezil compared to no treatment was
associated with 0.13 QALYs gained per patient, and 0.01 QALYs gained per caregiver and resulted in average
savings of €7,007 and €9,893 per patient from the healthcare system and societal perspectives, respectively. In
patients with moderate to moderately-severe AD, donepezil compared to memantine resulted in QALY gains
averaging 0.01 per patient, and savings averaging €1,960 and €2,825 from the healthcare system and societal
perspective, respectively.
In probabilistic sensitivity analyses, donepezil dominated no treatment in most replications and memantine in over
70% of the replications. Donepezil leads to savings in 95% of replications versus memantine.
Conclusions: Donepezil is highly cost-effective in patients with AD in Germany, leading to improvements in health
outcomes and substantial savings compared to no treatment. This holds across a variety of sensitivity analyses.
Background
Alzheimer’s disease (AD) is an incurable neurodegenera-
tive disease characterized by cognitive decline, impair-
ment of daily activities and neuropsychiatric symptoms.
AD patients lose the ability to perform higher-level daily
activities and decrease to being no longer able to per-
form basic daily necessities such as eating or grooming
[1]. Mood swings, apathy, psychosis or agitation are
behavioral symptoms commonly observed with AD
patients. With increasing severity of the disease dealing
with the patients’ symptoms can become an increasing
burden to caregivers.
A recent study reported the prevalence of dementia in
Germany a under 1% of 60-64 year olds and significantly
increasing to roughly 20% for those over the 85-89 year
olds, up to three quarters of whom had AD [2]. Recent
estimates for Germany placed the number of individuals
with moderate of severe dementia at just over 1 million,
with a projected increase of AD patients in Germany of
over 2 million by 2050 [2]. Against the background of
an aging population, the German Federal Government
has recently intensified its focus on dementia. In 2008,
the “Leuchtturmprojekt Demenz” with a budget of 13
million Euro was initiated to improve the evidence-
based medical and care service provision for dementia
patients [3].
Despite the fact that the benefit of cholinesterase inhi-
bitors have been established by numerous studies [4,5]
and that they are a recommended treatment for AD [6],
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given drug acquisition cost considerations [7]. Research
on the cost effectiveness of cholinesterase inhibitors is
therefore important to provide decision makers with the
best possible economic evidence to determine whether
concerns over drug acquisition costs are legitimate.
Over the last decade, numerous studies have measured
the cost-effectiveness of treatments for AD [8,9], most eval-
uating the cost-effectiveness of cholinesterase inhibitors.
Eight studies have investigated donepezil [10-17], with all
but one indicating that donepezil was cost-effective. In
Germany, a recent study showed that donepezil was also
cost-effective in the German setting, with a base case esti-
mated cost-effectiveness ratio of €4,264 per CDR–Clinical
Dementia Rating Scale gained [18].
Previous cost-effectiveness studies have modeled AD
progression in terms of cognitive function alone, func-
tional status alone, a single global severity measure, or
progression to the need for “Full Time Care”. Our study
uses an alternative modeling approach to estimate dis-
ease progression in terms of correlated changes in cog-
nition, behavior and function. The model was initially
constructed for analyses set in the UK [19].
Methods
The discrete event simulation developed for the evalua-
tion of donepezil’s cost-effectiveness in the UK [19,20]
was adapted for Germany. The model calculates out-
comes from the perspective of both the statutory health
insurance and care insurance (Gesetzliche Krankenversi-
cherung/Soziale Pflegeversicherung, GKV/SPV), and
from the societal perspective. The GKV/SPV perspective
encompasses direct medical costs borne by statutory
healthcare insurance including drug costs, costs for
monitoring and service provision as well as patient care
costs borne by long-term care insurance. The societal
perspective comprises both direct and indirect costs, the
latter including costs of caregiver time. A discount rate
of 3.0% was used for both costs and benefits [21]. In the
base case analyses, the time horizon is 10 years in order
to capture all potential benefits over the course of the
disease.
Model overview
To allow for individual level modelling, discrete event
simulation was used as the modeling technique, captur-
ing heterogeneity in disease progression and other out-
comes, as well as tracking correlated changes on
multiple domains on continuous rather than aggregated
discrete scales. The approach also allows for persistence
with treatment to be captured, factoring in time-depen-
dence and the impact of treatment discontinuation on
both costs and disease progression in a realistic manner
[22-24].
Previous economic evaluations in AD have measured
outcomes using highly aggregated health states, and
thus were not able to capture the benefits associated
with treatment in adequate detail. Furthermore, they
have often modeled the disease either based on single
domains (e.g., MMSE–Mini-Mental State Examination)
or global domains (e.g., CDR–Clinical Dementia Rating
Scale), losing the ability to capture the effects of treat-
ment on the full spectrum of AD symptoms. This was
driven in part by limitations in data accessible to ana-
lysts and the difficulty of tracking progression on multi-
ple measures using traditional Markov model
techniques. In addition, most of these models were
designed as cohort models with no ability to account for
individual characteristics in predicting outcomes, varia-
bility in outcomes over the course of the disease or
other relevant factors that might influence important
determinants of long term outcomes, such as persistence
with treatment. The shortcomings of modeling studies
in AD have been extensively debated in the literature
[8,9,25,26].
Our study adopts an alternative approach in an
attempt to overcome some of these limitations. First, it
addresses limitations of existing models that focus on a
single measure of disease severity alone to model the
evolution of AD, by modeling the disease using mea-
sures of cognition, behaviour and function. Second, it is
an individual simulation that is not encumbered by the
limitations imposed by Markovian structures such as an
inability to account for individual characteristics by rely-
ing on cohort mean values or the use of aggregate
health states (e.g., mild, moderate, severe; full-time care,
pre-full time care) instead of continuous measurement
of disease progression. Finally, as the model employed
in this study is an individual patient simulation, it allows
for consideration of variation in patient characteristics
and disease progression, allows for simulation of persis-
tence with treatment, implementation of clinical stop-
ping rules, and time varying treatment effects and is
therefore able to capture disease progression and treat-
ment effects with greater accuracy. The model has been
built using ARENA (Version 11) software.
Figure 1 provides an overview of the model flow. First,
simulated patients are created and individual, unique
attributes are assigned. Each patient is then copied twice
and the three identical patients are assigned to either no
treatment, donepezil 10 mg or memantine 20 mg.
Patients are then followed over the course of the simula-
tion with their characteristics updated over time. The
simulation measures disease severity based on cognition
(using the MMSE), behaviour (using the Neuropsychia-
tric Inventory, NPI), activities of daily living (ADLs) and
instrumental activities of daily living (IADL). In order to
preserve the correlation amongst these measures of
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sequentially predict changes in MMSE, followed by NPI,
ADLs, and IADLs. Changes in cognition are first pre-
dicted for a simulated individual, which then influence
changes in NPI, ADLs, and IADLs. Furthermore, changes
in ADL scores are used as part of the prediction of
changes in IADL scores. Based on a given patient’sc h a r -
acteristics at any point in time, including treatment status
and current disease severity, costs, health utilities and
caregiver outcomes are calculated and accumulated over
the appropriate time period. The model also reports time
spent with non-severe symptoms as defined by MMSE,
N P I ,A D Lo rI A D Ls c o r e s .M M S Es c o r e sb e l o w1 0w e r e
assumed to represent severe disease according to cur-
rently accepted definitions for severe cognitive impair-
ment. For NPI, a cluster analysis of psychiatric symptoms
using the NPI of 122 Alzheimer’s disease patients in the
US [27] was used as the basis for assigning a threshold of
28 for the NPI as representing highly symptomatic
behavioral disturbances. IADL and ADL thresholds were
arbitrarily set to their mid-point values of 50.
In the simulation, patients can discontinue treatment
either based on pre-defined stopping rules, or for other
unrelated reasons. As there are currently no defined
stopping rules in Germany (e.g., stopping treatment
when MMSE scores fall below 10), this option has only
been explored in the sensitivity analyses. Mortality is
also modeled, although given that neither cholinesterase
inhibitors nor memantine have been associated with
improvements in survival, time of death is assigned to
each individual prior to treatment assignment, thereby
ensuring that survival is identical in all groups.
Data sources
Population
An individual patient data set constructed using baseline
information from donepezil clinical trials [28-30] is
sampled from, to create simulated patients. Characteristics
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Figure 1 Simplified representation of the Alzheimer’s disease simulation flow.
Hartz et al. BMC Neurology 2012, 12:2
http://www.biomedcentral.com/1471-2377/12/2
Page 3 of 12carried in the model include patient age, sex, use of psy-
chiatric medications, MMSE, NPI, ADL- and IADL scores,
as well as caregiver age and sex. The trials chosen to pro-
vide the sample patients were those that had data on as
many target variables as possible, and taken together
include all AD severity levels [19].
The age and sex distributions of AD patients in Ger-
many [31] were used to assign sampling weights to indivi-
duals in the data set in order to ensure that the age and
sex profile of the simulated population was consistent with
that of the German AD patient population. Furthermore,
analyses are specified according to subgroups of interest,
so that sampling is restricted to the relevant population
(e.g., patients with mild to moderate AD, as defined by
baseline MMSE scores).
Disease progression and treatment effects
To improve on existing economic evaluations by includ-
ing the effects of disease on behavior and function, data
were analyzed from the CERAD (Consortium to Estab-
lish A Registry for Alzheimer’s Disease) registry [32],
and seven donepezil clinical trials in AD [28-30,33-36],
including data from open label extensions of two of the
studies [37,38]. Trial data included 2,700 patients from
the US, Canada, UK, France, and five Nordic countries,
with up to 52 weeks of follow-up. The inclusion of trials
in the current analyses was based on several criteria.
Most importantly, to develop equations related to dis-
ease progression and treatment effects, access to patient
level data was required. In selecting trials to be included
in the patient level analyses, studies had to be Phase III
or later, had to include a measure of baseline MMSE,
and had to include at least one of the effectiveness out-
comes included in the model. Studies conducted in spe-
cial populations (e.g., women only, Apo-E subtypes,
nursing home residents only); or of open label design
only were excluded, as were dose finding studies.
While MMSE data over time were available from trial
data the patterns of change observed in CERAD were
more consistent with previous findings on progression
of AD in untreated patients [39-41] and were therefore
used to model the natural history of cognitive changes
in the absence of treatment. A piecewise linear regres-
sion model was fitted to the annual rate of change in
MMSE. This approach allows for a different slope in dif-
ferent intervals of the MMSE scale to reflect differences
in the rate of change at different disease stages. Vari-
ables considered included patient age at baseline, sex,
disease duration, baseline MMSE, and rate of decline in
the first year (labeled PrevRate). The following MMSE
equation was derived, retaining variables significant at
the 0.05 level:
RateofChange = −5.4663 − 0.4299PM1 − 0.0042PM2 +0 . 1 4 1 5 PM3 − 0.0791PrevRate
+0.0747Age + δi
PM represents patients’ previous MMSE measure-
ment, partitioned over the MMSE scale. PM1–PM3 are
calculated as: PM1 = min(PrevMMSE, 9), PM2 = max[0,
min(PrevMMSE-9, 9)], and PM3 = max[0, min(Pre-
vMMSE-18, 12)]. δi represents a random intercept para-
meter, allowing the pattern of decline to vary between
patients. The MMSE scale itself ranges from 0 to 30.
To apply a treatment effect for donepezil, a similar
model was fitted to the donepezil trial data to identify
differences in rate of cognitive decline [19]. In the first
20 weeks of treatment, the estimated coefficients for
treatment effect on annual rate of change was 6.16 and
2.47 over weeks 20 to 52. After 1 year, further treatment
was assumed to simply maintain previous gains (i.e. the
treatment term in the rate of change equation is set to
0). Note that these coefficients are not the sole determi-
nant of treatment effect size given that rate of change in
MMSE is also influenced by individuals’ previous rate of
decline and overall disease severity. Furthermore, the
coefficients for treatment effect influence the annual
rate of change, and are applied differentially depending
on time on treatment and how long patients remain on
treatment. In order to test the validity of the effect size
calculations, simulated effect sizes at 6 months were
compared to the observed effect sizes in the clinical
trials [20], with the simulation resulting in an estimate
of improvement of 1.92 points on the MMSE for done-
pezil versus no treatment, compared to the observed
1.88 point difference.
NPI was predicted based on the donepezil trials where
NPI data were collected. It was modeled as change from
NPI at baseline.
ChangeNPI = (5.74 − 0.64Donepezil +0 . 0 3 Weeks − 0.59NPIbase − 0.001NPI ￿ Weeks
+0.24NPIrecent − 1.74White − 3.82Black +2 . 3 4 PsyMed +0 . 1 2 MMSEbase − 0.22MMSErecent + δi) ￿ 1.44
Donepezil represents the treatment effect of donepezil,
Weeks stands for weeks of follow-up in the simulation,
NPIbase is the patient’s baseline NPI, NPIrecent is the
patient’s last NPI. White and Black are dummy variables
for race (All Other Races was the reference), PsyMed is
a dummy variable for patients treated with psychiatric
medications at baseline, MMSEbase represents the
patient’s MMSE at baseline, and MMSErecent represents
the patient’s previous MMSE. δi represents a random
intercept parameter, which allows the pattern of decline
to vary between patients. Patient age and sex, as well as
rate of MMSE decline were also tested as predictors,
but failed to reach a significance level of 0.05. The equa-
tion for NPI was derived based on a normalized scale of
0 to 100, and is therefore multiplied by 1.44 to rescale it
to the standard 0 to 144 range for the NPI.
As changes in NPI are influenced by patients’ baseline
and most current MMSE, the treatment effect of done-
pezil is realized both through the treatment coefficient
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ment effect coefficient, therefore, only partially accounts
for the impact of treatment on NPI changes, as patients
on treatment will generally have better MMSE scores.
For example, a patient who has a 1 point treatment
effect on MMSE, will experience a total treatment effect
on NPI of 1.44*[(-0.22 × 1) -0.64], or -1.27.
For the scales that measure function (ADL and IADL)
standardized scales ranging from 0 (best function) to
100 (worst function) were created based on the available
clinical trial data.
As with NPI, ADL and IADL equations predict change
from baseline:
RateofChangeADL =1 . 3 5− 0.81Donepezil +0 . 0 6 Weeks − 0.79ADLbase +0 . 7 1 ADLprevious
+0.12MMSEbase +0 . 0 9 Age +0 . 8 1 PsyMed − 3.05Black − 0.49MMSErecent + δi
RateofChangeIADL = 1.27 + 0.63Donepezil +0 . 1 7 Weeks − 0.06Donepezil ￿ Weeks − 0.84IADLbase
+0.002IADLWeek +0 . 8 4 IADLprevious − 0.67Male +0 . 2 0 MMSEbase − 0.28MMSErecent
−0.16ADLbase +0 . 1 8 ADLrecent + δi
Age stands for the patient’s age at baseline in years.
Potential predictors considered for inclusion (at 0.05
level) were treatment, time, baseline and most recent
ADL/IADL, baseline and most recent MMSE, baseline
and most recent NPI, age, sex, treatment, and use of
anti-psychotic medications.
For ADL scores, donepezil’se f f e c tw a sm o d e l e d
directly through the treatment effect and the terms for
patients’ most recent MMSE. For IADLs, treatment
comes into play through the treatment term, as well as
patients’ most recent MMSE and ADL scores.
Additional technical details on the equations used in
the simulation have been published elsewhere [19].
Standard errors and a validation that simulated results
on treatment effect from the predictive equations and
compare well to observed results on treatment effect are
also available [20], although IADL treatment effect sizes
were underestimated at 6 months. For NPI, the simu-
lated treatment effect size was 1.75 points compared to
the observed 1.68 for ADL, the simulated effect size was
2.55 points compared to an observed 2.59 and for
IADLs, the simulated effect size was 1.69 points com-
pared to an observed 3.79.
As head-to-head data were not available for meman-
tine, the simulation predicts disease progression and
treatment persistence for patients on memantine using
the parameters for patients on donepezil, but modifies
these parameters using the difference between 6-month
placebo adjusted clinical trial results for memantine
20 mg and donepezil 10 mg in moderate to severe AD
patients (Table 1). Data for memantine were extracted
from a Cochrane meta-analysis [42].
Persistence
Patients can stop treatment in the simulation either by
reaching the end of the user-specified treatment
duration (10 years in base case), based on clinical stop-
ping rules (e.g., MMSE falling below 10 as explored in
the sensitivity analyses), or other non-specified reasons.
The analyses are based on the assumption that patients
who stop treatment lose all treatment benefits over the
course of the subsequent 6 weeks [37].
Hazard ratios for premature treatment discontinuation
are derived from the donepezil clinical trial data and
applied to base discontinuation rates derived from actual
practice data in the UK [43] (Table 2) as there are no
equivalent data available for Germany. The hazard ratios
are based on a Cox regression model in which MMSE
and the rate of decline in MMSE were updated over
time. Demographic variables were also tested as predic-
tors of discontinuation but were not significant (0.05)
and not retained.
Mortality
German-specific survival data were obtained from the
German Federal Statistical Office [44]. As there are no
disease specific survival data for Germany available, gen-
der-specific differences in survival for the UK and Ger-
man populations aged 65 years and older were applied
to survival times from the Medical Research Council’s
cognitive function and ageing study (MRC CFAS), and
time to death functions derived based on patient age
and gender at baseline [45]. Mortality was assumed to
be unaffected by treatment.
Medical costs
Daily treatment costs of €4.20 for donepezil 10 mg and
€3.83 for memantine 20 mg were derived from the Rote
Liste
®.[46]. Patients on active therapy were assumed to
incur costs associated with biannual visits to their physi-
cian. Costs for outpatient service provision, such as GP
or specialist visits, dementia tests, laboratory tests or
imaging are based on the German tariff EBM 2008 [46].
Direct patient care costs per disease state are based on
a 2007 publication on the cost effectiveness of donepezil
in Germany [18,47], and inflated to 2008 Euros, using
the harmonized index of consumer prices for Germany
[48]. It provides monthly costs by severity level which
were interpolated to provide estimates for intermediate
disease severity stages (Table 3). The same cost was
applied regardless of location of care because health
state costs included costs for both ambulatory care and
nursing homes.
Table 1 Changes in placebo-adjusted effectiveness
outcomes for donepezil and memantine
Outcome Donepezil Memantine Difference
MMSE (0-30) 1.16 0.48 -0.68
NPI (0-144) -2.40 -2.76 -0.36
Function (0-100) -4.44 -2.35 2.09
Relative Risk of Drop-Out 1.18 0.66 0.62
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Caregiver time was linked to disease severity parameters
[20] based on an equation derived from two of the
donepezil clinical trials where these data were available,
and took the form of [29,30]:
CareMinutesPerDay = 76.41 + 1.8Agecg + 93.02Malecg + 85.56Malepatient − 6.47MMSE
+0.58NPI +2 . 6 6 ADL +2 . 6 1 IADL + 20.55PsyMed
Agecg stands for the caregiver’s age, Malecg is a dummy
variable for the caregiver’ss e x ,a n dMalepatient for the
patient’s sex. Patient age and relation of patient to care-
giver (spouse, child, or other) were other parameters
tested but dropped for lack of significance with p >
0.10. The p-value for PsyMed was 0.25 but it was
retained as it was a confounding variable (i.e., dropping
it biased the values of the other coefficients).
In sensitivity analyses, an alternative assignment of
caregiver time was used, with caregiver time calculated
based solely on patient’s MMSE score using estimates
reported for Germany [47]. Caregiver time was valued at
€5.21 per hour based on a published study [18,47].
Location of care
Costs and time by location of care are accumulated
based on the severity of disease patients experience over
the course of the simulation. Similarly, time spent by
patients in institutions is allotted as percentage of the
time that the patient was alive. Institutionalization rate
was calculated based on institutionalization rates of AD
patients in Germany [50] which were reported as 42.9%
for patients with MMSE scores below 20, and 0% for
those with scores of 20 or higher. In order to produce a
finer gradient, these results were fit to a simple linear
regression which predicted the proportion of patients
institutionalized as 64.35% - 2.86% × MMSE, with rates
varying from 0% for those at the mildest stages of the
disease to 50% for those with severe AD.
Health utilities
Patients’ health utilities were estimated based on a pre-
viously published regression equation [51] which used
the EQ-5D to derive health utilities for 272 AD patients
in Nordic countries [19]. The NPI term in the published
equation was based on the brief NPI, and was modified
to reflect the full NPI range (0 to 144) used in the simu-
lation. The final equation took the following form and is
applied in the model by using patients’ values (e.g.,
MMSE score) over the course of the simulation to cal-
culate the appropriate QALYs to be assigned to that
patient:
Utility =0 . 4 0 8+0 . 0 1 0 MMSE − 0.004NPI − 0.159Institutionalized +0 . 0 5 1 Caregiver
MMSE represents the patient’s current MMSE, NPI
represents the patient’sc u r r e n tN P I .Institutionalized is
a dummy variable for whether the patient is institutio-
nalized. Caregiver indicates whether the patient lives
with their caregiver.
Caregiver utilities are assigned based on equations
derived from the donepezil trial data where caregivers
completed the SF-36 [20,28-30]. Scores were trans-
formed to health utilities [52] and a linear repeated
measures model was used to develop the following
equation:
Table 2 Baseline discontinuation rates for patients on donepezil and memantine
Months 0-3 Months 0-6 Months 6-12 Annual Risk After 12 Months
Donepezil 5.1% 5.1% 10.2% 10.3%
Memantine 3.1% 3.1% 6.3% 6.3%
Table 3 Cost inputs
Care costs by disease severity (MMSE) Monthly costs Source
Mild ≥ 25 €184 Adapted from Teipel et al. 2007[18]
≥ 20 - < 25 €593
Moderate ≥ 15 - < 20 €1,275
≥ 10 - < 15 €1,958
Severe < 10 €2,981
Drugs Treatment costs
per day**
Source
Donepezil 10 mg €4.20 Rote Liste
® 2008[49]
Memantine 20 mg €3.83 Rote Liste
® 2008[49]
Outpatient treatment monitoring Costs per quarter Source
GP visit, geriatric assessment, MMSE test (one per quarter) €53.47* EBM2008[46]
* Including once-quarterly lump-sum for GP visit (€37.74), geriatric assessment (€ 13.69) and MMSE test (€2.04)
** Treatment costs per day are calculated based on the N3 package price provided in the Rote Liste
® converted to a daily cost based on the number of tablets
per pack
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−0.001ADL − 0.0004IADL − 0.01PsyMed
Patient sex and relation of patient to caregiver
(spouse, child, or other) were other variables tested but
dropped for lack of significance with p > 0.10. PsyMed
and IADL had p-values of 0.20 but were retained as they
were confounders.
Analyses
Base case analyses were run for patients with mild to
moderate AD (26 ≥ MMSE ≥ 10) treated with donepezil
10 mg versus no treatment, and for patients with mod-
erate AD (MMSE 10-19) on donepezil versus meman-
tine 20 mg over a 10 year time horizon.
The following parameters were varied in the probabil-
istic sensitivity analyses: treatment effects on MMSE,
NPI, ADL, and IADL, patient care costs, caregiver time
regression parameters, patient and caregiver utility
regression parameters, the proportion of patients living
in the community by disease severity, and treatment dis-
continuation rates.
Standard errors were available for many parameters
from the parameter source data, reflecting the study
sampling error. Where standard errors were not avail-
able, 25% of the parameter mean was used to assign an
assumed 95% confidence interval from which standard
error estimates were derived. A normal distribution was
assumed for parameters on continuous variables, while
proportion parameters on discrete variables were
assumed to be beta distributed.
Results
In patients with mild to moderately severe AD (26 ≥
MMSE ≥ 10), donepezil dominates no treatment from
both the GKV/SPV perspective, with savings averaging
€7,007 per patient (€7,323 undiscounted). From the
societal perspective where savings increase to €9,893 per
patient (€10,384 undiscounted) (Table 4), donepezil
treatment is associated with an increase in QALYs aver-
aging 0.13 per patient (0.14 undiscounted). For care-
givers, donepezil treatment increases QALYs by 0.01
compared to caregivers of untreated patients (0.02
undiscounted). Donepezil also increases the amount of
time patients spend with MMSE scores above 10 by an
average of 24 weeks per patient, NPI scores below 28 by
almost 6 weeks, and ADL/IADL scores below 50 by
more than 7 and 3 weeks, respectively. In patients with
moderate including moderately-severe AD (20 > MMSE
≥ 10), donepezil also dominates memantine, although
savings are smaller, averaging €1,960 per patient (€2,097
u n d i s c o u n t e d )f r o mt h eG K V / S P V -a n d€2,825 per
patient (€3,012 undiscounted) from the societal perspec-
tive. QALY gains are clearly smaller, with donepezil
associated with an average QALY gain of 0.01 per
patient versus memantine (0.01 undiscounted), and care-
giver QALYs gained at less than < 0.001. The reduction
in time patients spend institutionalized also falls by just
over 10 days per patient. For patients with moderately
severe AD, donepezil still dominates no treatment,
although consistent with findings in the UK [20]. Cross
reference Getsios 2010, per patients savings were lower
at €8,043, as were both patient and caregiver QALYs
gained, at 0.120 and 0.013, respectively. Memantine also
led to lower overall costs and improved QALYs relative
to no treatment, although both savings and QALYs
gained, although savings were 35% lower compared to
those with donepezil, and QALYs gained 13% lower.
In one-way sensitivity analyses key parameters such as
caregiver time, costs, utilities, institutionalization and
treatment effects were varied. Regardless of the varia-
tion, donepezil remained dominant compared to both
no therapy and memantine. Rates of treatment disconti-
nuation and the duration of treatment had the strongest
influence on the extent of savings and health benefits
(Table 5).
In probabilistic sensitivity analyses, donepezil dominates
n ot r e a t m e n ti na l m o s ta l lr e plications from both the
health care payer and societal perspectives (Figure 2). Ver-
sus memantine, donepezil dominates in 70% of replica-
tions, and leads to savings in 95% of replications (Figure 3).
For the analyses versus memantine, at a threshold of
10,000 Euro/QALY, donepezil was cost-effective from both
perspectives in over 90% of replications.
Discussion
T h ed i s c r e t ee v e n ts i m u l a t i on developed for donepezil
provides a flexible framework for the assessment of treat-
ing AD patients with donepezil. By integrating patients’
individual characteristics, heterogeneity in the population,
disease progression and outcomes can be captured. Dis-
ease progression was modeled not solely relying on 1 year
RCT data, but also using longer term CERAD registry
data, which allows for a more realistic representation of
the disease course. The model allows for analysis of popu-
lation subgroups, with different settings for time horizon,
treatment duration, discontinuation rules, and treatment
effects. Cost, utility and caregiver inputs can be specified
for different severity ranges and locations of care, or can
be specified using predictive equations, making adaptation
of the model and incorporation of new data easier.
T h ea n a l y s e sf o rG e r m a n yi n d i c a t et h a td o n e p e z i li s
clearly cost-effective in the treatment of patients with
mild to moderately-severe AD. In the base case and all
one-way sensitivity analyses, donepezil dominated no
treatment and memantine in all scenarios evaluated.
Results of the probabilistic sensitivity analyses were also
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in virtually all replications, and leading to savings in the
comparison with memantine in 95% of replications. With
the availability of generic cholinesterase inhibitors, cost
savings should be even greater, although the contribution
of the cost of treatment with donepezil to overall costs is
modest, representing less than 2.5% of total costs in
patients with mild to moderately-severe AD.
Our model differs from most previous economic mod-
els in AD in that we model disease progression over
several domains using continuous scales, rather than
using a single domain and/or limiting outcomes to a
small number of discrete health states. Although more
favorable overall with donepezil predicted to dominate
no treatment, the results of this study are much more in
line with previous findings for Germany [19], where a
base-case ICER of €4,264 per QALY for donepezil ver-
sus placebo was estimated. That study also indicated
that starting treatment early leads to cost reductions
and therefore improved cost-effectiveness. The more
favorable predictions from our simulation are chiefly a
result of the greater sensitivity of our model in captur-
ing changes in cognition, and in the case of indirect
costs, the consideration of not only cognition, but also
patient function and behavioral symptoms.
The current simulation is not without limitations. For
example, the longest-duration of head to head clinical
trial data available was for 1 year versus placebo [29].
Table 4 Base case results by disease severity for the 10 years following treatment initiation*
Patients with MMSE ≥ 10 and ≤ 26 versus untreated patients Untreated Donepezil Net difference
Survival (undiscounted, in years) 4,870 4,870 0,000
Drug Costs € 0 € 4,625 €4,625
Total Non-Drug Direct Costs €126,863 €115,231 -€11,632
Total Direct Costs €126,863 €119,856 -€7,007
Indirect Costs €87,138 €84,253 -€2,885
Total Costs €214,001 €204,108 -€9,893
Years with MMSE > 10 1,972 2,435 0,463
Years with NPI < 28 2,680 2,794 0,114
Years with ADL < 50 1,896 2,036 0,140
Years with IADL < 50 0,241 0,303 0,062
Years in Institution 1,663 1,457 -0,206
Total Care Time (Years) 1,908 1,845 -0,063
QALYs (Patient) 1,659 1,790 0,131
QALYs (Caregiver) 3,272 3,287 0,014
QALYS (Patient + Caregiver) 4,931 5,077 0,146
Health Care Direct Cost/QALY (Patient + Caregiver) Dominant
Societal Total Cost/QALY (Patient +Caregiver) Dominant
Patients with MMSE ≥ 10 and < 20 versus memantine Memantine Donepezil Net difference
Survival (undiscounted, in years) 4,909 4,909 0,000
Drug Costs €4,972 €4,696 -€276
Total Non-Drug Direct Costs €129,702 €128,019 -€1,684
Total Direct Costs €134,674 €132,715 -€1,960
Indirect Costs €89,572 €88,707 -€ 865
Total Costs €224,246 €221,422 -€2,825
Years with MMSE > 10 2,023 2,801 0,058
Years with NPI < 28 2,808 2,751 -0,058
Years with ADL < 50 1,772 1,835 0,062
Years with IADL < 50 0,186 0,209 0,023
Years in Institution 1,702 1,673 -0,028
Total Care Time (Years) 1,961 1,942 -0,019
QALYs (Patient) 1,663 1,677 0,014
QALYs (Caregiver) 3,276 3,279 0,003
QALYS (Patient + Caregiver) 4,939 4,956 0,017
Health Care Direct Cost/QALY (Patient + Caregiver) Dominant
Societal Total Cost/QALY (Patient +Caregiver) Dominant
*All outcomes are presented at discounted values
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year serves as a maintenance function only with no
further slowing of the rate of disease progression, we
have adopted a conservative approach consistent with
most other modeling studies in this area. Furthermore,
we assume that all benefits are lost within 6 weeks if
treatment is discontinued. Comparisons with memantine
are subject to even greater uncertainty, as no head-to-
head trial data are available, requiring indirect compari-
sons based on pooled trial results. Clearly, incorporation
of head to head clinical trial data versus memantine
would strengthen comparisons and yield more robust
Table 5 One-way sensitivity analyses
Analysis QALYs Total
costs
Cost per
QALY
QALYs Total
costs
Cost per
QALY
Patients with
MMSE 10-26:
donepezil versus
no treatment
Patients with
MMSE 10-20:
donepezil versus
memantine
Base Case 0.146 -€9,893 Dominant 0.017 -€2,825 Dominant
Caregiver Time Effects of Disease Severity ↓ 25%
† 0.146 -€9,171 Dominant 0.017 -€2,608 Dominant
Patient Care Cost ↓ 25%
‡ 0.146 -€6,911 Dominant 0.017 -€2,417 Dominant
Patients institutionalized ↓ 25% 0.135 -€9,893 Dominant 0.015 -€2,825 Dominant
Patient Utility Effects of Disease Severity ↓ 25% 0.124 -€9,893 Dominant 0.015 -€2,825 Dominant
Stop Treatment if MMSE < 10 0.132 -€11,006 Dominant 0.018 -€2,279 Dominant
Stop Treatment if MMSE Deteriorates on any Scale after 6 Months 0.140 -€9,691 Dominant 0.054 -€4,578 Dominant
5 Year Time Horizon 0.140 -€10,172 Dominant 0,016 -€2,578 Dominant
Treatment Effects ↓ 25%
† 0.107 -€5,930 Dominant 0.023 -€3,379 Dominant
No Discontinuation 0.204 -€13,215 Dominant 0.041 -€4,301 Dominant
Double Discontinuation 0.106 -€7,412 Dominant 0.003 -€1,760 Dominant
Treatment Duration 5 Years 0.140 -€10,171 Dominant 0.016 -€2,580 Dominant
Treatment Duration 1 Year 0.042 -€2,704 Dominant 0.008 -€991 Dominant
Alternative caregiver time effect (German data)[47] 0.146 -€16,677 Dominant 0.017 -€3,288 Dominant
Alternate disease severity definition based on German convention MMSE
ranges *
0.151 -€9,486 Dominant 0.019 -€3,448 Dominant
† Coefficients in regression equations relating to disease severity (MMSE, NPI, ADL, and IADL) were reduced by 25%
‡ All patient care costs were reduced by 25%
* Mild MMSE ≥ 18, moderate MMSE 10-17, severe MMSE < 10
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Figure 2 Cost-effectiveness scatter plot for patients with 26 ≥ MMSE ≥ 10: donepezil versus no treatment. Distribution of replications:
0.8% in upper right quadrant (donepezil leads to incremental costs and higher QALYs), 99.2% in lower right quadrant (donepezil dominant,
leading to lower costs and higher QALYs).
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Page 9 of 12results. In addition, the current analyses evaluate mem-
antine monotherapy versus donepezil monotherapy.
Although memantine also be used as an add-on treat-
ment to cholinesterase inhibitors, this was not evaluated,
as the focus of these analyses was on the cost-effective-
ness of donepezil, and not memantine.
T h es o u r c ep o p u l a t i o nf o rt h et r i a ld a t aw a sn o tG e r -
man, though it was weighted for the age and sex distri-
bution of German AD patients when defining the
simulated population. Other limitations of the data
revolve around assigning costs and utilities associated
with different degrees of disease severity. A recent
review paper on health utilities [53] used in economic
evaluations, noted the limited amount of data on sever-
ity specific health utilities in populations with AD, and
the poor correlation between patient-based utilities, and
those derived by caregiver proxy.
The cost data for Germany are based entirely on MMSE
ranges (i.e., they do not consid e rb e h a v i o ro rf u n c t i o n ) .
Furthermore published German cost data for AD at the
time of the analysis were scant, with only one publication
providing suitable information [47]. A number of studies
on dementia and AD costs were published in 2011
[52,54-56]. Those studies that did report costs by severity
of disease [52,54,55], all found that costs increase mark-
edly with increased disease severity, consistent with the
data used in the current model and therefore would not
alter our conclusions. The one study that examined costs
in patients with AD, for example [54] found that the
annual costs of the disease average €13,080 per patient per
year (€ 2009), but approached €25,000 per patient for
those at the most severe stages of the disease, compared to
well under €7,000 per patient for those at the most mild
stages. Finally, although wide variation exists in the valua-
tion of informal care, with donepezil dominant over no
treatment and memantine, even when these costs are con-
sidered, the method of assigning costs to caregiver time
would only influence the extent of savings associated with
donepezil. Of note, however, the hourly costs assigned to
caregiver time are substantially lower than those used in
recent German costing studies in dementia [52,54,55].
Conclusions
These analyses indicate that donepezil is highly cost-
effective in the treatment of mild to moderate AD in
Germany, and is likely associated with significant cost
savings when compared to untreated patients. While
benefits over memantine are modest, the base case and
sensitivity analyses results suggest a high likelihood that
donepezil would lead to cost savings if used in place of
memantine.
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